Esperion Therapeutics, Inc. (ESPR) — SC 13G/A Filings
All SC 13G/A filings from Esperion Therapeutics, Inc.. Browse 13 SC 13G/A reports with AI-powered summaries and risk analysis.
SC 13G/A Filings (13)
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 12, 2024
- SC 13G/A Filing — Nov 4, 2024
- SC 13G/A Filing — Oct 17, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 13, 2024
-
Wasatch Advisors LP Boosts Esperion Therapeutics Stake to 12.6%
— Feb 9, 2024 Risk: low
Wasatch Advisors LP, an investment adviser, has updated its ownership in Esperion Therapeutics, Inc. (ESPR) through an SC 13G/A filing on February 9, 2024. The -
BB Biotech AG Maintains 4.19M Share Stake in Esperion Therapeutics
— Jan 24, 2024
BB Biotech AG, a Swiss investment company, has filed an amendment to its Schedule 13G, indicating a change in its beneficial ownership of Esperion Therapeutics, -
Millennium Management Updates Esperion Therapeutics Stake
— Jan 17, 2024
Millennium Management LLC, a New York-based investment firm, filed an amended SC 13G/A on January 17, 2024, indicating its ownership of Esperion Therapeutics, I -
Meditor Group Discloses 3.3% Passive Stake in Esperion Therapeutics
— Jan 3, 2024
Meditor Group Ltd. and Meditor European Master Fund Ltd., both based in Bermuda, have updated their ownership stake in Esperion Therapeutics, Inc. As of Decembe
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX